The ARR at month 6 was significantly lower in ... 1.25 mg and 25.6% for placebo/fingolimod 5.0 mg. Similarly, Multiple Sclerosis Functional Composite (MSFC) scores showed negligible fluctuation ...
met its coprimary outcomes of decreased ARR and decreased accumulation of disability. This led to the initiation of several Phase III trials. [34] Preliminary results from CARE-MS II (NCT00548405 ...
Merck said that ARR for oral teriflunomide was lower than ... our aim was to address the significant unmet need of smouldering MS in addition to strong relapse control for people living with ...
Hosted on MSN5mon
Roche’s BTK inhibitor shines in multiple sclerosis trialIn Roche’s study, 96% of patients treated with fenebrutinib were free of relapses at one year, with an annualised relapse rate (ARR ... people living with multiple sclerosis.’’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback